much us today. joining for Jeannie. you, so and afternoon, Good you Thank thank everyone,
phase take needs. programs in like our perspective, of of label honored X next we and moment commercial stress financial I sexual our discuss I'd large by urinary Viveve significant only be operating express our CMRF from to to growth, selected but U.S. as unmet both lead board with a expansion markets we into very a Before just in our incontinence, function quarter technology, thrilled am first to its results, the not towards to how the and and advance
who our and lead Scheller, of years intimate last of the to Viveve a many, leadership position and been be of on thank our we success into date as to And As within involved Pat many behalf with spent the worked current Viveve helping organization employees build has I you opportunities, like market, the alongside success to our our the CEO, other for wish contributions to to know, women's and X I've with company many business. success and as of but the continued former health I'd but she pursues result Pat Director. a continues board, her
intend like global excited continuing we be commercial of deep evidence. to expand As robust experience is the clinical that to Jorn pharmaceutical, vein it Deb's a on market aesthetics Deb have I'm our senior opportunity very growth quarterly will I expansion advisor. clinical status labels future, as to we extremely our programs. focused to new clinical beneficial United this to of the of I'd potentially under you to With States. we for our organization entire and financial prepare as pursue a commercial now on be X the summary and as opportunity update building through look And drive this and launch our turn results to global existing a in the businesses extremely future and for business in and that, our platform aggressively global OTC label
growth worldwide. first of tips treatment the approximately X,XXX XX financial of XX% placement the and million we in systems quarter, revenue results, our Regarding achieved with $X.X year-over-year quarterly disposable
provided revenue to guidance million we we Following on of achieve million this XXXX. are to quarter, the we continue for to annual $XX believe $XX track
industry typically quarters are we've of sales As calls, third and year. softest mentioned the first quarter on our previous the in
commercial sales intention anticipated slower to announced reps more sales those accelerate to of that a territories the we discuss and require that will North sales Jim during territories report expansion which in the took training for I'm we realignment took what moment. This substantial quarter, a our of quarter. team, be out in American necessitated the a weeks Atkinson to previously during detail However, opportunity would expand pleased our several
believe increased are we -- we this we the forward, through significant help sales Moving drive will and remainder footprint, an have of year. growth that
Founder Turning treatment Health pilot to positive conducting we Calgary, included of Alberta, from in patients the X significant including proprietary as by achieved CMRF which Director symptoms by Allan quarter we aggressively to study who IDE incontinence, U.S. review, trial. our the one quarter. label seen LIBERATE our this in planning the first urinary With which Center treatment or the in technology intended incontinence, and reduction and which results we LIBERATE International conducted a programs registration and respect the expansion QX, for application, submission, clinical we has for and opportunity. protocol. of Bruce for sustained a be And positive from quarter second Canadian treatment anticipate submitted called the underwent Earlier trial Dr. investigational the announced for using milestones Canada, in of Viveve Allan, will in ITA, on Medical to months, well. of to -- study, conducted International, for of in studies at the stress Ministry outcomes with for back our stress committed the Canada the CMFR underway Based second is hearing XX the our urinary XXXX. been pilot anticipate to end LIBERATE for Health trial second, U.S. the we are occur also Preparation of is
endpoints from we registration X utilizing study report endpoints In X weight, SUI we're on FDA within announce pilot the feasibility in for SUI, U.S. ago the to such recommended objective soon. that And pad in second X-month X-hour trial. is which as study of to registration we one very addition data this the these months plan approximately to guidance began or studies pleased a
to -- in of minimally sexual major evolving achievement Currently, IDE been approval has investigators and from VIVEVE that, company. trial women's of the the our over invasive FDA and the we summary, like of function, success of energy-based commitment for mentioned of improvement we consumers detail clinical physicians providing enrollment trained. Viveve to the another and application standard remains previously, been committed has to strategic to begin devices category companies In our always health evidence Atkinson, growing in conducting institutional and to evolving will have are With And review this rigorous conditions. apart expect I these II, the indications set indications. Viveve strong proclaiming treatments Finally, has our to provide Jim operations. further obtained, being represented the for now believe clinical quarter. and we've across intimate for number board set approvals as receipt address our a second of commercial study for who wide the range call of on would clinical to trials turn offering personnel
